LoBuglio A F, Saleh M N
University of Alabama, Comprehensive Cancer Center, Birmingham 35294-3300.
Am J Med Sci. 1992 Sep;304(3):214-24. doi: 10.1097/00000441-199209000-00011.
Tumor-associated antigens can be seen as unique targets for the delivery of anti-cancer therapy. Monoclonal antibodies directed at such antigens are increasingly being seen as important biologic reagents that will complement the group of existing cytotoxic drugs. This report briefly overviews recent advances in the field of monoclonal antibody therapy of cancer and provides insight regarding the promises and limitations of this novel therapeutic approach.
肿瘤相关抗原可被视为抗癌治疗的独特靶点。针对此类抗原的单克隆抗体越来越被视为重要的生物试剂，将补充现有的细胞毒性药物类别。本报告简要概述了癌症单克隆抗体治疗领域的最新进展，并对这种新型治疗方法的前景和局限性提供了见解。
